Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 11;88(15):1454-1460.
doi: 10.1212/WNL.0000000000003821. Epub 2017 Mar 10.

Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients

Thomas E Lloyd  1 , Iago Pinal-Fernandez  1 , E Harlan Michelle  1 , Lisa Christopher-Stine  1 , Katherine Pak  1 , Ned Sacktor  1 , Andrew L Mammen  2
Affiliations

Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients

Thomas E Lloyd et al. Neurology. .

Abstract

Objective: To characterize patients with myositis with HIV infection.

Methods: All HIV-positive patients with myositis seen at the Johns Hopkins Myositis Center from 2003 to 2013 were included in this case series. Muscle biopsy features, weakness pattern, serum creatine kinase (CK) level, and anti-nucleotidase 1A (NT5C1A) status of HIV-positive patients with myositis were assessed.

Results: Eleven of 1,562 (0.7%) patients with myositis were HIV-positive. Myositis was the presenting feature of HIV infection in 3 patients. Eight of 11 patients had weakness onset at age 45 years or less. The mean time from the onset of weakness to the diagnosis of myositis was 3.6 years (SD 3.2 years). The mean of the highest measured CK levels was 2,796 IU/L (SD 1,592 IU/L). On muscle biopsy, 9 of 10 (90%) had endomysial inflammation, 7 of 10 (70%) had rimmed vacuoles, and none had perifascicular atrophy. Seven of 11 (64%) patients were anti-NT5C1A-positive. Upon presentation, all had proximal and distal weakness. Five of 6 (83%) patients followed 1 year or longer on immunosuppressive therapy had improved proximal muscle strength. However, each eventually developed weakness primarily affecting wrist flexors, finger flexors, knee extensors, or ankle dorsiflexors.

Conclusions: HIV-positive patients with myositis may present with some characteristic polymyositis features including young age at onset, very high CK levels, or proximal weakness that improves with treatment. However, all HIV-positive patients with myositis eventually develop features most consistent with inclusion body myositis, including finger and wrist flexor weakness, rimmed vacuoles on biopsy, or anti-NT5C1A autoantibodies.

PubMed Disclaimer

Figures

Figure
Figure. Evolution of muscle strength in patients with HIV-myositis followed longitudinally using locally weighted regression
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rider LG, Miller FW. Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA 2011;305:183–190. - PMC - PubMed
    1. Dalakas MC. Inflammatory muscle diseases. N Engl J Med 2015;373:393–394. - PubMed
    1. Griggs RC, Askanas V, DiMauro S, et al. . Inclusion body myositis and myopathies. Ann Neurol 1995;38:705–713. - PubMed
    1. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008;70:418–424. - PubMed
    1. Hiniker A, Daniels BH, Lee HS, Margeta M. Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies. Acta Neuropathol Commun 2013;1:29. - PMC - PubMed